Biopharmaceutical march 2015

BIOPHARMACEUTICAL
R2
R1
CH
HO
OH
INVESTMENT
OPPORTUNITIES
IN KOREA

BIOPHARMACEUTICAL
INVESTMENT
OPPORTUNITIES
IN KOREA
KOREA,
Where Success Knows No Limits
Contents
04 Industry overview
The pharmaceutical industry
Biotech industry
10 Competitive standing and outlook
Global market outlook
Future development of pharmaceutical and biotech industries
18 Government policies and related regulations
Government policies by industry
22 Cost
24 Success cases
28 Related companies and associations

0501 INDUSTRY OVERVIEW
The pharma-
ceutical
industry
INDUSTRY
OVERVIEW
Korea’s pharmaceutical market stood at KRW 19.291 trillion (USD 17.3 billion)* in 2013, up 0.3%
YoY, and posted a five-year CAGR of 2.3% from 2008 to 2013. Given that the market recorded
a higher growth rate than the global market until 2010, its growth pace has slowed. However,
Korea’s pharmaceutical market continues on a steady growth path despite the global economic
crisis.
•In particular, it is notable that Korea’s pharmaceutical production increased by 4.1% YoY,
to KRW 16.2 trillion, in 2013, departing from a stagnant growth trend since 2010. Korea’s
pharmaceutical exports posted a 2008 - 2013 CAGR of 13% driven by Korean pharmaceutical
companies with a growing presence in the global market.
•In contrast, Korea’s pharmaceutical imports dropped 10% YoY, to KRW 5.2 trillion in 2013,
contributing to a sharp decline in trade deficits.
In a nut shell, Korea’s pharmaceutical industry records modest growth across the board. As
Korean pharmaceutical companies have steadily sharpened their competitiveness, the Korean
industry has increased exports and production volumes and fast reduced trade deficits.
Korea’s pharmaceutical industry employed 78,259 individuals in 2013, up 5.1% YoY, or 3,782
individuals. This marks an upturn in pharmaceutical employment, breaking from a downward
trend since 2010, and indicates that business activities have recently gained momentum in
Korea’s pharmaceutical industry.
Recent developments in Korea’s pharmaceutical industry
(Unit: KRW million)
2008 2009 2010 2011 2012 2013 %YoY
A 5-year
CAGR
Production 13,893,810 14,788,387 15,569,588 15,440,251 15,560,663 16,191,845 4.1% 3.1%
Export 1,255,891 1,772,242 1,770,059 1,943,493 2,309,534 2,318,522 0.4% 13.0%
Import 4,319,756 4,953,881 5,108,911 5,447,053 5,728,874 5,155,829 -10.0% 3.6%
Trade
balance
-3,063,865 -3,181,639 -3,338,852 -3,503,560 -3,419,340 -2,837,308 -17.0% -1.5%
Market size 16,957,675 17,970,026 18,908,439 18,943,812 18,980,003 19,029,152 0.3% 2.3%
* Source: Korea Health Industry Development Institute (2014), Analysis of Korea’s Pharmaceutical Industry (2013)
* Currency conversion based on March 10, 2015 rate.

0706 BIOPHARMACEUTICAL 01 INDUSTRY OVERVIEW
Pharmaceutical researchers numbered 5,437, accounting for 6.9% of the total workforce in
Korea’s pharmaceutical industry. As much as 70.2% of researchers have master’s or doctoral
degrees and the research workforce structure was based mostly on higher-skilled talent.
Number of people employed in Korea’s pharmaceutical industry
82,000
80,000
78,000
76,000
74,000
72,000
70,000
2008
75,406
2009
81,204
2010
77,314
2011
74,477
2012
78,259
Research workforce breakdown by educational background
(Unit: People)
Others
107
B.S. degree
holders
1,509
Ph.D. holders
637
M.S. degree
holders
3,184
The biotech industry uses biotechnologies based on DNA, protein and cells to produce various
products, such as biopharmaceuticals, and to create value-added services.The industry includes
biopharmaceuticals, bioengineered food, biochemicals and bio-environment, bioelectronics,
bio-process and device, bio-energy resources, others such as biological assay (assessment) and
bioinformatics services.
Korea’s biotech industry stood at KRW 7.52 trillion in 2013, up 5.3% YoY, in terms of domestic
sales and exports, and posted a high CAGR of 8.9% from 2009 to 2013.
In terms of production value, the bioengineered food segment is the largest contributor, with
annual production of KRW 3.21 trillion in 2013, accounting for 40% of the biotech industry. The
second-largest contributor is biopharmaceuticals, with annual production of KRW 2.78 trillion.
Biochemicals and other biotech segments are small in terms of absolute production value but
expand at a fast pace, raising expectations that they will represent an increasing share of the
biotech industry’s production.
Korean biotech industry production (domestic sales + exports)
(Unit: KRW million)
Year Production Total Biopharmaceuticals Biochemicals Bioengineered food Other
2009
Domestic sales 2,907,448 1,564,251 260,356 283,954 601,718
Export 2,728,749 1,209,223 69,907 722,474 371,403
2010
Domestic sales 3,346,287 1,521,210 230,073 989,797 605,207
Export 2,441,539 852,028 60,352 1,356,334 172,825
2011
Domestic sales 3,646,896 1,506,329 355,684 1,065,834 719,049
Export 2,749,356 954,412 74,783 1,531,965 188,195
2012
Domestic sales 4,068,644 1,577,572 408,226 1,261,325 821,521
Export 3,060,585 1,139,980 97,173 1,610,631 212,802
2013 Domestic sales 4,357,396 1,636,942 451,091 1,338,933 930,430
Export 3,166,435 1,138,462 111,110 1,682,131 234,731
%YoY
Domestic sales 7.10% 3.76% 10.50% 6.15% 13.26%
Export 3.46% -0.13% 14.34% 4.44% 10.30%
CAGR
(2009 - 2013)
Domestic sales 10.64% 1.14% 14.73% 47.36% 11.51%
Export 3.79% -1.50% 12.28% 23.53% -10.84%
* Source: Korea Statistical Information Service (www.kosis.kr)
The domestic biotech market stood at KRW 5.87 trillion in 2013, up 6.1% YoY, posting a CAGR of
8.5% from 2009 to 2013.
•By segment, the biochemicals segment posted the fastest growth, at 8.5% YoY. Of other
biotech segments, the bioelectronics and bio-environment segments recorded a high growth
rate of 53.8%YoY and 9.6%YoY, respectively, although their domestic sales were relatively low,
at KRW 37.3 billion and KRW 30.3 billion.
Biotech
industry

0908 BIOPHARMACEUTICAL 01 INDUSTRY OVERVIEW
In terms of domestic sales, biopharmaceuticals are the largest segment, accounting for 50%
of the biotech market. However, biopharmaceuticals record a slower growth rate than other
segments, while bioengineered food and biochemicals marked higher growth rates.The biotech
market is expected to grow beyond biopharmaceuticals to include diverse segments such as
biochemical, bioengineered food and other biotech segments.
Size of Korea’s biotech market (domestic sales + import)
(Unit: KRW million)
2009 2010 2011 2012 2013 %YoY
CGAR
(2009 - 2013)
Total 4,236,695 4,751,946 5,208,078 5,643,437 5,866,853 3.96% 8.48%
Biopharmaceuticals 2,536,348 2,620,986 2,736,657 2,819,494 2,961,578 5.04% 3.95%
Biochemicals 372,034 324,505 435,402 476,952 515,177 8.01% 8.48%
Bioengineered food 317,692 999,180 1,098,907 1,320,973 1,385,571 4.89% 44.51%
Other 813,452 807,273 937,112 1,026,018 1,004,527 -2.09% 5.42%
* Source: Korea Statistical Information Service (www.kosis.kr)
The number of companies in Korea’s biotech industry increased by 13, from 958 in 2011 to 971 in
2012, marking an upward trend.
•By segment, the number of biotech companies increased in the biopharmaceuticals,
biochemicals and other segments but slightly declined in the bioengineered food segment.
In 2013, the number of people employed by biotech companies stood at 38,197, marking an
increase of 627 individuals from 2012. In other words, the average number of employees per
biotech firm stood at 39.3.
The number of researchers amounted to 11,605 individuals, or 30.4% of the employees in Korea’s
biotech industry. About 60% of researchers have master’s or doctoral degrees. The workforce is
highly skilled in the biotech industry, as seen in the pharmaceutical industry.
Changes in number of biotech companies
1,000
900
800
700
600
500
400
300
200
100
0
Total
913
276
188 202
247
971
317
203 199
252
Biopharmaceuticals Biochemicals Bioengineeredfood Other
958
305
204 199
250
2011 2012 2013
* Source: Biotech Industry Study (2014)
Workforce structure of Korea’s biotech industry
Segment
People Doctoral degree Master’s degree Bachelor’s degree Other
Share (%) People People People People
Biopharmaceuticals
18,469 1,030 3,519 6,877 7,043
100% 6% 19% 37% 38%
Biochemicals
4,936 362 1,355 1,937 1,282
100% 7% 27% 39% 26%
Bioengineered food
8,070 345 1,298 3,527 2,900
100% 4% 16% 44% 36%
Other
6,722 359 1,239 3,079 2,045
100% 5.34% 18.43% 45.80% 30.42%
Total
38,197 2,096 7,411 15,420 1,285
100% 5.49% 19.40% 40.37% 3.36%

1110 BIOPHARMACEUTICAL 02 COMPETITIVE STANDING AND OUTLOOK
The global pharmaceutical and biotech markets have steadily expanded thanks to an aging
population and growing awareness of healthy lifestyles worldwide.
•The global pharmaceutical industry expanded 2.4%YoY, to USD 959 billion in 2012, and posted
a high CAGR of 5.3% from 2007 to 2012. The growth rates are relatively low compared to the
pre-crisis growth rate of about 8%. However, the global pharmaceutical industry has continued
on a steady growth path despite a global economic slowdown, as national healthcare spending
and demand for healthcare have increased amid aging populations in Asia.
•TheglobalbiotechmarketamountedtoUSD1.18trillionin2012.Thisglobalindustryisoneofthe
mostpromisingandexpectedtoreachUSD1.57trillionin2015,witha2010-2015CAGRof9.7%.
Size and growth outlook of the global biotech market
Year Value (USD billion)
Growth rate (%)
%YoY CAGR
2010 987.2 9.1% 9.7%
2011 1,079.0 9.3% 9.7%
2012 1,181.5 9.5% 9.7%
2013 1,298.4 9.9% 9.7%
2014 1,434.7 10.5% 9.7%
2015 1,572.4 9.6% 9.7%
* Source: IMS Health (2012)
The future development of the pharmaceutical and biotech industries is expected to be led by
technology convergence-driven new industries, such as BIT.
•The“ubiquitous”healthcare industry has emerged thanks to IT-related innovative technologies,
creating new medical device markets such as portable diagnostic devices for remote health
monitoring, remote consultation and remote treatment.The personalized healthcare market is
estimated to reach USD 63.9 billion in 2015, from USD 33.7 billion in 2010.
Thanks to dramatic technological developments in DNA analysis, key product categories will
include chips and diagnosis kits based on DNA sequencing and protein analysis.
•The preventive medicine segment, such as the introduction of biosensors and biomarkers, is
expected to develop thanks to growing demand for products that enable fast diagnosis and
early detection, for disease prevention. The development of personalized target therapy and
companion biomarkers (companion diagnostics) are expected to emerge as a new business
model for the pharmaceutical industry.
COMPETITIVE
STANDING
AND OUTLOOK
Global market
outlook
Future
development
of pharma-
ceutical and
biotech
industries

The industry shift from one-size-fits-all products to personalized treatment products should be
accelerated.
•Medicinal treatment and management will take into consideration personal genetic
information and physical traits, departing from the practice of applying the same treatment
to all patients. In this regard, development of the single-nucleotide mutation search, precision
diagnosis and monitoring segments will enable drug response prediction and help establish a
system to fend off trial and error and side effects in advance.
DiagnosisofKorea’scompetitiveness
Korea accounts for 1.8% of the global pharmaceutical market and 1.7% of the biotech market
in terms of sales revenue. Korea’s biotech and pharmaceutical markets are small in absolute
terms but have overtaken the global market in terms of growth rates. For example, Korea’s
bioengineered food segment has posted a five-year CAGR of more than 50%, and the domestic
sales and exports of biotech products, such as bio-chemicals and biopharmaceuticals, recorded a
CAGR of 20 - 30%. Given the brisk pace of market growth and active business, Korea is expected
to enhance its competitiveness in the global market.
•Korea’s biotech industry is expected to maintain strong growth momentum and record KRW
20 trillion in production and KRW 13 trillion in domestic sales in 2017.
•The fast growth of the biotech industry is attributed to socio-demographic and demand and
supply-side factors, among others. On the socio-demographic side, the biopharmaceuticals
and bio diagnostic device segments have been expanding quickly thanks to growing demand
for health checkups, disease prevention and geriatric treatment amid an aging population and
longer life expectancy.
•On the demand side, the biopharmaceuticals, bio-cosmetics and bioengineered food
segments have been rapidly growing due to an increase in disposable income and standard of
living and a greater desire for a healthy, younger life.
•On the supply side, as national spending on social welfare and public health has increased
due to an aging population, it is increasingly important to meet social demand in a more cost-
effective way. As such, the biotech industry has been a target of active national investments
and efforts to develop technology. Developing further on scientific achievements, the biotech
industry has been leading national and industrial efforts to generate new growth momentum
for industrial development.
Competitivenessofthepharmaceuticalindustry
Korean pharmaceutical companies have mostly developed generic drugs. However, the
development of new drugs is more important than ever to meet changes in the pharmaceutical
environment. As such, industry players, especially major pharmaceutical companies, have
strengthened their commitment to investing in new drug development.
•The need to develop new drugs is gaining momentum due to government policies and
changes in the domestic and foreign pharmaceutical market. Therefore, the commitment and
investment of major pharmaceutical companies in new drug development are becoming
more important.
•Korean pharmaceutical companies have delivered achievements in biosimiliar and
incrementally modified drugs (IMD), capitalizing on their knowhow and research expertise,
and made significant efforts to develop first-in-class drugs. As a result, Korean companies
have exported technologies to multinational companies and conducted global clinical trials,
earning recognition for their technological prowess. For example, Hanwha Chemical exported
its biosimilar version of Pfizer’s blockbuster rheumatoid arthritis drug Enbrel, and Hanmi
Pharmaceutical has licensed out its Poziotinib, a targeted anti-cancer treatment.
Korean pharmaceutical companies made research and development (RD) investments worth
KRW 967.2 billion in 2012. The RD investment posted a high CAGR of 13.7% over the past five
years, reflecting a growing commitment to RD.
•In addition, the average concentration ratio of the pharmaceutical industry increased from
6.24 in 2008 to 7.67 in 2012 in the RD segment. Such an increase in RD activities, which are
essential to the development of the pharmaceutical industry, raises expectations that Korea
will be able to enhance its competitiveness.
Korean pharmaceutical companies have actively sought partnerships with global pharmaceutical
companies. For example, Hanwha Chemical concluded an agreement with Merck to produce and
globally market the biosimilar of arthritis blockbuster Enbrel. Samsung BioLogics established a
biosimilar joint venture with the U.S.-based Biogen Idec, enhancing comprehensive partnerships
in areas such as RD, manufacturing and marketing. As such, cooperation with multinational
pharmaceuticals is expected to generate strong synergy effects.

The therapeutic antibodies segment is among the most promising in the pharmaceutical
industry. Korea’s therapeutic antibodies market increased from KRW 30 billion in 2006 to KRW 83
billion in 2010. If the domestic development of new therapeutic antibodies speeds up, Korea’s
therapeutic antibodies segment will reach KRW 300 billion in 2015.
•ISU ABXIS recorded KRW 3.3 billion in sales with Clotinab, Korea’s first antibody-based
treatment. Celltrion has actively conducted RD in therapeutic antibodies, winning approvals
for its infliximab biosimilar Remsima and completing the phase III clinical trial of the biosimilar
Herceptine (breast cancer treatment).
Outlook for the Korean therapeutic antibodies market
(Unit: KRW 100 million)
Market size
3,000
2,500
2,000
1,500
1,000
500
0
300
830
3,000
* Source: Ministry ofTrade, Industry Energy, Five-year Plan forTechnology Innovation (2013)
Competitivenessofthebiotechindustry
Given that Korea is one of the countries with the most rapidly aging population, the outlook
for demand in the biotech industry is positive. In addition, the biotech industry is expected
to continue on a growth path driven by government support and the commitment of large
corporations to new business development.
Accordingly, Korean companies increase their RD investments to secure their competitiveness
in the biotech industry. Korea’s biotech RD investments reached KRW 1.165 trillion in 2013,
continuing on a growth path.
•Korea ranks fifth among OECD member countries, following the United States, France, Japan
and Germany in terms of the private sector’s investments in the biotech segment. In addition,
the biotech segment accounts for 20% of the Korean government’s investments, the second
largest among OECD member countries, following Germany.
•Statistics show that the Korean government has played a key role in establishing the scientific
foundation for biotech research. The public sector’s efforts have facilitated the private sector’s
investments and put the biotech industry on the path to growth and development.
Korea’s new drug development
Company New drug Development stage
Celltrion Remsima (anti-rheumatic drugs )
World’s first biosimilar antibody (approved in
July 2012 in Korea, June 2013 in EU)
Celltrion Biosimilar Herceptin (breast cancer treatment)
Phase III clinical trial (completed in Asia in
November 2010)
Dong-A ST Tedizolid phosphate (super bacteria antibiotics) FDA approval (April 2014)
LG Life Sciences Zemiglo (anti-diabetic drug)
Phase III clinical trials and sales right agreement
(June 2012)
Chong Kun Dang
Pharmaceutical
CKD-732 (anti-obesity drug) Phase III clinical trials underway (October 2014)
Pharmicell Hearticellgram (myocardial infarction treatment) World’s first stem cell treatment (July 2011)
Medipost CARTISTEM (knee cartilage regeneration treatment) KFDA approval (January 2012)
Antrogen Cupistem injection (Crohn's disease treatment) KFDA approval (January 2012)
Core Stem HYNR-CS injection (ALS treatment) KFDA approval (July 2014)
RD investments by Korean pharmaceutical companies
(Unit: KRW million)
1,000,000
800,000
600,000
400,000
200,000
0
2008
578,268
2009
648,362
2010
684,207
2011
813,755
2012
967,239
RD investments
* Source: Korea Health Industry Statistics System (KHISS)
RD concentration among Korean pharmaceutical companies
(Unit: %)
9,00
8,00
7,00
6,00
5,00
4,00
3,00
2,00
1,00
0,00
2008
6.24
2009
6.50
2010
6.44
2011
7.41
2012
7.67
RD concentration rate
* Source: Korea Health Industry Statistics System (KHISS)

1716 BIOPHARMACEUTICAL
Korea’s biotech RD investments
RD investments
10,000
8,000
6,000
4,000
2,000
0
2008
7,293
2010
7,686
2009
8,761
2012
9,988
2011
9,302
By segment, major market players in the biotech industry are as follows.
Segment Major companies
Biopharmaceuticals Celltrion, Isu Abxis, Meditox, RNL Bio, JW-Shinyak, etc.
Biochemicals CJ CheilJedang, Daesang, SK, LG Chem, GS Caltex, Cheil Industries, etc.
Bioengineered food Daesang , CJ CheilJedang, Dongbu Farm Hannong, MOGHU Research Center, etc.
Bioelectronics and analytic device Humasis, Bio Focus, Nano Entek, K-MAC, Seegene, Bioneer
Other AmorePacific, LG Household HealthCare, Hankook Cosmetics, Pharmicell , Medipost, etc.
The in vitro diagnostic segment is expected to be among the fast-growing markets of the biotech
industry.The segment has strong growth potential thanks to new technology development and
a rapidly aging population.The market is estimated to reach KRW 420 billion in 2014.
Korea’s in vitro diagnostic medical device (IVDs) market
(KRW 100 million)
2009 2010 2011 2012 2013 2014
Bioelectronics 369 489 553 624 724 840
Bioinformatics biological assay 1,406 1,355 1,531 1,730 1,955 2,209
Bio diagnostics
(20% of the diagnostic test market)
600 690 780 881 996 1,125
Total 2,375 2,534 2,864 3,235 3,675 4,174
* Source: Ministry ofTrade, Industry Energy, Five-year Plan forTechnology Innovation (2013)
•In particular, the bio-convergence segment has strong growth potential thanks to Korea’s
technological capabilities in the semiconductor and IT segments, and Korean electronics
companies are showing growing interest in the bio-convergence segment.
-This segment includes biochips, biosensors, u-healthcare and diagnostic devices. In particular, the biochip and
biosensor markets have demonstrated significant growth potential and delivered strong performance.
•In this regard, the development of bio chips has been led by public research institutes and
universities such as the Korea Institute of Science Technology (KIST), Electronics and
Telecommunications Research Institute (ETRI), Korea Electronics Technology Institute (KETI),
Korea Advanced Institute of Science andTechnology (KAIST), Pohang University of Science and
Technology (POSTECH), Seoul National University (SNU) and private research institutes and
large corporations such as Samsung Advanced Institute of Technology (SAIT), LG Electronics
Tech Center and LG Chem. Recently, an increasing number of biotech startups have been
entering the market.
•Of Korea’s IVD market, companies such as HBI, SD, Humasis, Bio Focus, Nano EnTek and K-MAC
are new entrants in the immune segment, and companies such as Seegene and Bioneer have
DNA diagnosis products and globally competitive technologies in the molecular diagnosis
segment.
•In addition, as the focus of healthcare has shifted from treatment to disease prevention due to
an aging population, the personalized healthcare market is expected to fast expand, enabling
routine and customized health care through early diagnosis, a ubiquitous healthcare system
and personal health records.
02 COMPETITIVE STANDING AND OUTLOOK

Korea’spharmaceuticalindustry
The Korean government announced in July of 2013 the Five-year Comprehensive Plan for
the Support and Development of the Pharmaceutical Industry in an effort to promote the
pharmaceutical industry. In a fast-changing pharmaceutical industry, the Korean government
has launched a five-year initiative to encourage Korean pharmaceutical companies to go global
through the development of new drugs and products, departing from growth strategies focused
on generic drugs and the domestic market.
•The five-year plan envisions that Korea will join the top 10 in the global pharmaceutical
industry by recording pharmaceutical exports worth KRW 11 trillion and creating four world-
class new drugs by 2017 through five core tasks, 13 key strategies and 41 action plans.
In September of 2013, the Ministry of Health andWelfare launched a fund worth KRW 100 billion
specializing in the pharmaceutical industry to promote high-risk investments by pharmaceutical
companies.The specialized fund is financed by the Ministry of Health andWelfare, Korea Finance
Corporation, Korea Development Bank and Korea Securities Finance Corporation. Its objective
is to support Korean pharmaceutical companies in their technology partnerships and overseas
expansion and to invest in small- to mid-size tech startups with weak financing capacity. The
first global pharmaceutical fund started investments in promising Korean pharmaceutical
companies such as Genexine, Crystal Genomics, DiNonA and CorenTec in 2014, providing growth
momentum for Korea’s pharmaceutical industry.
The Korean government has pursued the PB 300 Project, which provides Korean companies
with consulting and advisory services, by recruiting leading experts from overseas as short-
term consultants. The objective of the PB 300 Project is to ensure that the government can
help Korean companies tackle challenges and enhance their capability by providing consulting
services with a talent pool of overseas experts in new drug RD, planning, clinical trials,
manufacturing, approval and technology marketing.With the help of the PB 300 Project, Korean
companies that have technologies but lack clinical trial experience overseas will be able to
expand to global markets and emerge as globally competitive players by acquiring advanced
technologies and know-how, enhancing their competence in developing and marketing their
technologies and products.
GOVERNMENT
POLICIES AND
RELATED
REGULATIONS
Government
policies by
industry
03 GOVERNMENT POLICIES AND RELATED REGULATIONS

To increase awareness of Korea’s pharmaceutical products in the global market, the Korean
government has assisted Korean companies in their expansion to new emerging markets,
enhancing government-to-government collaboration and sending private-public market
development delegations. During Bio Korea 2013 (September 11-13, 2013), Pharm Fair was held
on the sidelines to bring together related foreign authorities in the drug approval segment and
promote marketing cooperation with overseas drug distribution companies. Pharm Fair created
an opportunity for Korean pharmaceutical companies to generate businesses worth KRW 170
billion, including the USD 100 million export deal between BC World Pharm and KOA SHOJI
(Japan). Such policy efforts should help Korean companies look beyond the domestic market,
reach out to the rest of the world and become globally competitive players.
The Korean government introduced a pilot procedure combining drug approval and price
evaluation from October to December of 2013, to shorten the time-to-market for new drugs
and the evaluation period of drug list prices and thus establish an efficient infrastructure for new
drug development.
Thebiotechindustry
The government has designated the healthcare industry as one of the pillars of and core tasks
for Korea’s transition toward a “creative economy.” It has made nation-wide efforts to increase
investments, raise private funds, develop a talent pool and enhance infrastructure efficiency.
•For this goal, the government has set out key initiatives to develop Korea as one of the top
ten players in the global pharmaceutical industry and enhance strategic healthcare RD by
increasing RD competence in personalized healthcare, stem cell rehabilitation medicine,
new drugs medical devices and conversion betweenWestern and traditional medicines.
In addition, according to the 2nd
Basic Development Plan for Bioengineering (2012), the Korean
government will increase biotech investments to KRW 9.7 trillion through 2016 and is developing
a research talent pool of 73,222 master’s or doctoral degree holders.
Government RD investments in the biotech segment
2009 2010 2011 CAGR
Government RD 123,437 137,014 148,902 9.8%
Biotech RD 20,112 23,252 25,808 13.3%
Biotech RD as % of government RD 16.3% 17.0% 17.3% -
The Korean government announced in July of 2013 the “Government-wide Mid- to Long-term
Action Plans to Promote RD for National Healthcare,” integrating policy plans established
by ministries responsible for the biotech and healthcare industries. Moreover, the Korean
government seeks to increase public investments and ease investment restrictions in an effort to
promote private investments.
As part of a private-public initiative to promote the biochemicals sector, a total of KRW 250
billion will be invested for a five-year period from 2013. The Korean government is also making
efforts to establish a full-cycle RD system through collaboration with related companies and to
overhaul the system, which requires that public organizations prioritize the purchase of certain
products upon procurement. As such, various mid- to long-term initiatives are underway to
ensure Korea will be among the top five in the global biochemicals market by 2020.
•The Ministry of Trade, Industry Energy has launched a five-year biochemicals technology
development project worth KRW 215.5 billion in 2014 with the goal of accelerating the
development of technology and production infrastructure.
03 GOVERNMENT POLICIES AND RELATED REGULATIONS

The average annual salary at Korean pharmaceutical companies is USD 27,681, with the top 25%
at USD 42,987 and the bottom 25% at USD 15,903.The starting salary at major companies tends
to be higher at multinational companies than Korean companies and is distributed as follows.
Starting salary at major pharmaceutical companies
(Unit: USD)
Company Starting salary (USD)
GlaxoSmithKline 33,393
Korea Polyol 32,491
AstraZeneca Korea 31,769
Pfizer Korea 31,588
ISU Chemical 30,505
Dong-A Pharm 29,874
Yuhan Corporation 27,076
Dongwoo Fine-Chem 24,368
Average annual income is distributed as follows by academic background.
Average annual income by academic background
(Unit: USD)
Average salary
40,000
35,000
30,000
25,000
20,000
15,000
10,000
5,000
0
Associatedegreeholder
22,572
Master’sdegreeholders
32,139
Bachelor’sdegreeholders
28,384
Ph.D.holders
39,025
COST
04 COST

SUCCESS CASES
05 SUCCESS CASES
1) Celltrion: KRW 350 billion in investments from Temasek, Singapore’s sovereign wealth fund,
since 2010
•Celltrion attracted KRW 207.9 billion in investments fromTemasek, Singapore’s sovereign wealth
fund, in 2010 thanks to its superb biosimilar technologies and solid contract manufacturing
organization (CMO) business. Temasek acquired a 10% stake in Celltrion Healthcare, Celltrion’s
affiliate,andmadeanadditionalinvestmentofaboutKRW150billionin2013.
•Investment incentives and outcomes
Celltrion has expanded the global market coverage of Remsima, a biosimilar version of
Remicade (rheumatoid arthritis drug), winning regulatory approvals in Korea and Europe.With
the completion of a phase 3 clinical trial of the biosimilar Herceptine (breast cancer treatment),
the company has made significant achievements in the biosimilar segment.
•It was biosimilar capability that enabled Celltrion to attract foreign investments. Foreign
investments helped Celltrion repay its debts, raise operating capital, enhance its presence in
the global capital market and place a greater focus on developing biosimilar and therapeutic
antibody technologies.
2) Aprogen: Strategic partnership with Japan’s Nichi-Iko Pharmaceutical (2010) and exclusive
sales right worth KRW 30 billion (2014)
•Aprogen, a tech venture in the Daeduk Specialized Zone, attracted an investment of KRW
13.3 billion in the biosimilar business from Japan’s Nichi-Iko Pharmaceutical in 2010. Nichi-Iko
Pharmaceutical acquired a 33.4% stake in Aprogen and entered into an agreement to conduct
clinical trials, file for regulatory approval and sell Aprogen’s biosimilars in Japan. Afterwards,
Aprogen developed the Remicade biosimilar and entered into an exclusive supply contract
with Nichi-Iko Pharmaceutical for KRW 30 billion in 2014.
Aprogen is a subsidiary of Schnell Biopharmaceuticals and the first company in Korea to have
promoted the development of new drugs based on protein and antibodies. Aprogen was
established in 2000 by two professors from the Korea Research Institute of Bioscience and
Biotechnology (KRIBB) and KAIST and has transferred four biosimilar drug technologies to
other companies. Currently, the company is developing four kinds of biosimilars and three
kinds of protein-based new drugs. In addition, the company transferred its business right to
biosimilars of Ramicade (rheumatoid arthritis treatment) and Rituxan (anti-cancer drug) to
Schnell Biopharmaceuticals.
Aprogen attracted equity investments from Japan’s Nichi-Iko Pharmaceutical in 2010 to finance
its biosimilar production and facilitate its advancement in the global market. The agreement
in 2014 includes an investment clause that Nichi-Iko Pharmaceutical will provide capital for
Aprogen to build large-scale biosimilar production facilities. As such, Aprogen has secured
financing for its production facilities and an exclusive right to supply products.

3) Samsung BioLogics: Joint venture between Samsung and Quintiles Transnational Corp.
Samsung BioLogics has created a USD 300 million biosimilar development JV with Biogen Idec.
•Samsung and Quintiles Transnational Corp, a U.S.-based global clinical research service
provider, established Samsung BioLogics, a joint venture with KRW 300 billion in capital.
BioLogics teamed up with Biogen Idec to establish a joint venture that develops, manufactures
and sells biosimilars. Samsung BioLogics started construction of a biopharmaceutical plant
with a cell culture capacity of 30,000 liters in June of 2011, with plans to complete the pilot
production of therapeutic antibodies in August of 2014 and start mass production in 2015.
Samsung BioLogics has secured access to the global biotech industry by attracting foreign
investment. In addition, Samsung BioLogics is well-positioned to sharpen its competitiveness
in the biopharmaceutical segment, as it can share knowhow with a global company in
various areas such as contract manufacturing and preclinical and clinical trials. In addition,
the establishment of mass production facilities for biosimilars should allow the company to
expand biopharmaceuticals production, extend global market reach and accelerate RD.
4) Dong-A Pharm: Strategic partnership with GSK
•In May of 2010, Dong-A Pharm forged a strategic partnership with the global pharmaceutical
company Glaxo Smith Kline (GSK). GSK acquired a 9.9% stake in Dong-A Pharm to jointly
operate the sales, clinical trials and commercialization of ethical drugs. It is a comprehensive
partnership that enables Dong-A Pharm to secure a stable supply of GSK’s key pipeline drugs
and GSK to use Dong-A Pharm’s sales networks and marketing force in Korea. GSK and Dong-A
Pharm expanded their partnerships in March of 2012 to include over-the-counter (OTC) drugs,
generating synergy effects both in the OTC and ethical drug markets.
The partnership between GSK and Dong-A Pharm is an unprecedented model of partnership
between a global pharmaceutical company and a Korean pharmaceutical company. In
particular, GSK has identified Korea as an attractive investment destination, given Korea’s
RD capacity and clinical trial experiences, and thus showed great interest in Dong-A Pharm’s
overseas RD pipeline. Through partnerships, Dong-A Pharm has secured an opportunity to
learn global clinical expertise and successfully expand its global business.
5) Genexine: Ajinomoto Genexine, a joint venture with Ajinomoto
•Genexine, a Korean biotech venture, formed a joint venture, Ajinomoto Genexine, with
Ajinomoto in November of 2012 to produce cell culture media for biopharmaceutical
production. Ajinomoto has a 75% equity stake in the joint venture, which has KRW 35.7 billion
in capital. With the complement of the cell culture media production facilities at the end of
May 2014 in Songdo, Incheon, Ajinomoto Genexine can domestically produce Ajinomoto’s
patent-protected serum-free medium, which used to be imported, and plans to expand its
market presence, especially in Korea and Asia.
6) Investment incentives and outcomes
•Ajinomoto needed to establish a production base in Asia to meet growing demand for
biological research and biopharmaceutical production. As such, Ajinomoto formed a joint
venture with Genexine, a Korean biotech company with solid biopharmaceutical infrastructure
and promising RD networks. The joint venture makes it easier for Korean biopharmaceutical
companies to domestically procure customized cell culture media, which offer higher quality
than imported products. In addition, Ajinomoto Genexine is a good example of where a
competitive Korean biotech company has attracted foreign investment with its technological
prowess. It will pave the way for competitive biotech companies to further enhance their
technological competence and develop financing and marketing capacity by attracting
foreign investment and forging partnerships.
05 SUCCESS CASES

Relatedassociations
Name Website
Korea Biodiesel Association blog.naver.com/kbda0711
Korea New Renewable Energy Association www.knrea.or.kr
Korea Pellet Fuel Association cafe.naver.com/ilovepellet
Korea Bioplastics Association www.kbpa.net
Korea Bio Material Packaging Association www.biopack.or.kr
Korea Association of Geriatric Hospitals www.kagh.co.kr
Korean Hospital Association www.kha.or.kr
Korea Pharmaceutical Association www.kpanet.or.kr
Korea Medical Devices Selling Association www.komedia.or.kr
Korea Medical Association www.kma.org
Korea u-Health Association www.uha.or.kr
Korea Association of Health Promotion www.kahp.or.kr
Korea International Medical Association www.koreahealthtour.co.kr
Korea Global Healthcare Association www.kgha.kr
Korea Biopharmaceuticals Association www.ko-bia.or.kr
Korea Biotechnology Industry Organization www.koreabio.org
Korea Research Institute of Bioscience Biotechnology www.kbra.or.kr
Korea Biosafety Association www.kobsa.net
Korea Drug Research Association www.kdra.or.kr
Korea Medical Devices Industrial Coop www.medinet.or.kr
Korea Medical Devices Industry Association www.kmdia.or.kr
Korea Pharmaceutical Distribution Association www.kapw.or.kr
Korea PharmaceuticalTraders Association www.kpta.or.kr
Korea Pharmaceutical Manufacturers Association www.kpma.or.kr
Korea Food Industry Association www.kfia.or.kr
Korea Crop Protection Association www.koreacpa.org
Korea Seed Association www.kosaseed.or.kr
Korea Animal Health Product Association www.kahpa.or.kr
KoreanVeterinary Medical Association www.kvma.or.kr
Korea Advanced Farmers’Federation www.kaff.or.kr
Korea Animal Improvement Association www.aiak.or.kr
RELATED
COMPANIES AND
ASSOCIATIONS
06 RELATED COMPANIES AND ASSOCIATIONS

Relatedcompanies
Company Website
Gwangdong Pharmaceutical www.ekdp.com
Kukje Pharm www.kukjepharm.co.kr
Green Pharm ‐
BCWorld Pharm www.bcwp.co.kr
Kunwha Pharmaceutical www.kunwha.com
GlaxoSmithKline www.gskkorea.co.kr
Green Cross www.greencross.com
Daelim Pharmaceutical ‐
Daewoong Pharmaceutical www.daewoong.co.kr
Daewon Pharm www.daewonpharm.com
JW-Shinyak www.jw-shinyak.co.kr
Dai Han Pharm www.daihan.com
Daehwa Pharmaceutical www.dhpharm.co.kr
Dongkook Pharmaceutical www.dkpharm.co.kr
Huniz www.huniz.kr
Dong-A Pharm www.donga.co.kr
DongWha Pharm www.dong-wha.co.kr
Mundi Pharma mundipharma.co.kr
Medica Korea www.medicakorea.com
BiNex www.bi-nex.com
Baxter www.baxter.co.kr
Bolak www.bolak.co.kr
Boryung Pharm www.boryung.co.kr
Sewon Cellontech www.sewoncellontech.com
B. Braun Korea www.bbraun.co.kr
Bukwang Pharm www.bukwang.co.kr
Samnam Pharm www.samnam51.com
Samsung Fine Chemicals www.sfc.samsung.co.kr
Sama Pharm www.samapharm.co.kr
Samyang Biopharmaceuticals www.samyangpharm.co.kr
SamYang Chemical www.samyangchem.com
Samil Pharm www.samil-pharm.co.kr
Samjin Pharm www.samjinpharm.co.kr
Sam Chun Dang Pharm www.scd.co.kr
Saehan Pharm www.shpharm.co.kr
Company Website
Seoul Pharma www.seoulpharma.com
Suheung www.suheung.com
Hutecs Pharmaceutical www.hutecs.co.kr
SS Pharm www.susungpharm.com
Ahn Gook Pharm www.ahn-gook.com
RP Corp www.rpskorea.com
Pharmbio Korea www.pharmbio.co.kr
SB Pharmaceutical www.sbp.com
SK Chemicals www.skchemicals.com
Estech Pharma www.estechpharma.com
Dream Pharm www.dreampharma.co.kr
Nensys www.nensys.co.kr
LG Life Sciences www.lgls.co.kr
YD Diagnostics www.yd-diagnostics.com
Yungjin Pharmaceutical www.yungjin.co.kr
Youyoung Pharmaceutical www.yypharm.co.kr
Yuyu Pharma www.yuyu.co.kr
UK Chemi Pharm www.ukchemipharm.co.kr
Bioland www.biolandkorea.com
Yuhanmedica www.yuhanmedica.co.kr
Yuhan Corporation www.yuhan.co.kr
Ildong Pharmaceutical www.ildong.com
Ilsung Pharmaceutical www.ilsung-ph.co.kr
ILYANG Pharmaceutical www.ilyang.co.kr
Ilhwa www.ilhwa.co.kr
JRP www.jrpharm.co.kr
Kyowa Hakko Kirin Korea www.kyowa-kirin-korea.com
Jeil Pharmaceutical www.jeilpharm.co.kr
Choa Pharmaceutical www.choa.co.kr
Chong Kun Dang Pharmaceutical www.ckdpharm.com
JW Pharmaceutical www.cwp.co.kr
Jinyang Pharm www.jinyangpharm.com
Unimed Pharm www.unimed.co.kr
Chunggei Pharm www.chunggei.co.kr
Chodang Pharm www.chodang.com
KMS Pharm www.kmspharm.com

Company Website
Kolon Pharm www.kolonpharm.co.kr
Pharmicell www.pharmicell.com
Tai Guk Pharm www.taiguk.co.kr
Pharma King www.pharmaking.co.kr
Taejoon Pharm www.taejoon.co.kr
Pacific Pharm www.pacificpharm.co.kr
Richwood Pharmaceutical www.richwood.net
Fresenius Kabi Korea www.fresenius-kabi.co.kr
Hana Pharm www.hanaph.co.kr
Hawon Pharm www.hawonpharm.co.kr
Nelson Korea www.nelsonkorea.co.kr
PMG Pharm www.pmgpharm.co.kr
Daiichi Sankyo Korea www.daiichisankyo.co.kr
DPH Korea www.dhpkorea.co.kr
KoreaVaccine www.koreavaccine.com
Modern Cell TissueTechnologies www.mctt.co.kr
Han Kook ShinYak www.hsp.co.kr
Genexine www.genexine.com
Korea Arlico Pharm www.arlico.co.kr
Alcone Korea www.alconlabs.co.kr
Newgenpharm www.newgenpharm.com
Janssen Korea www.janssenkorea.com
Eisai Korea www.eisaikorea.com
Otsuka Pharmaceutical www.otsuka.co.kr
CR Research www.cnrres.co.kr
Korea Atomic Energy Research Institute www.kaeri.re.kr
Korea United Pharm www.kup.co.kr
Union Korea Pharm www.ukp.co.kr
Meid Help Line www.medihelpline.co.kr
CTC Bio www.ctcbio.com
Korea Ginseng Corp. www.kgc.or.kr
Hankook Korus Pharm www.koruspharm.co.kr
Korea Pharma www.koreapharma.co.kr
Pharvis Biotech Korea www.pharvis.co.kr
Ferring Pharmaceuticals www.ferring.co.kr
Korea Prime Pharma www.koreaprime.co.kr
Company Website
Astellas Pharma Korea www.astellas.com/kr
Handok Pharm www.handok.co.kr
Hanmi Pharm www.hanmi.co.kr
Hanbul Pharm www.hanbulpharm.co.kr
Celltrion www.celltrionph.com
Hanall Biopharma www.hanall.co.kr
Hanzhung Pharmaceutical www.hzpharm.co.kr
Hanpoong Pharm www.hanpoong.co.kr
HanWha Pharma www.hwpharm.com
CMIC CMO cmic-cmo.co.kr
Hyundai Pharm www.hyundaipharm.co.kr
Whanin Pharm www.whanin.com
Huons www.huons.co.kr
CJ Health Care www.cjp.co.kr
Isu Abxis www.abxis.com
GL PharmTech www.glpt.co.kr
MG www.medi-green.co.kr
YD Global Life Science www.bioyd.co.kr
Korea Global Pharm www.globalpharm.co.kr
Sungwon Adcock Pharm www.swpharm.com
Mcnulty Pharmaceutical www.mcnultypharm.com
Humedix www.humedix.com
Donwoo Syntech dongwookr.com
Samsung Bio Epis www.samsungbioepis.com
White Global Pharmaceutical Corp. www.whpharma.com
Crystal Genomics www.crystalgenomics.com
Bio Leaders www.bioleaders.co.kr

Supporting foreign investors worldwide
Headquarters
Address 13, Heolleung-no, Seocho-gu, Seoul, Republic of Korea
Tel (82-2) 1600-7119 Fax (82-2) 3460-7920
E-mail ikonline@kotra.or.kr
Homepage www.investkorea.org
NORTH AMERICA
New York, USA
Tel (212) 826-0900
E-mail kotrany@hotmail.com
Los Angeles, USA
Tel (323) 954-9500
E-mail info@kotrala.com
Chicago, USA
Tel (312) 644-4323
E-mail info@kotrachicago.com
Dallas, USA
Tel (972) 243-9300
E-mail joongik@kotradallas.com
Washington D.C., USA
Tel (202) 857-7919
E-mail washington@kotra.or.kr
Silicon Valley, USA
Tel (408) 432-5000
E-mail info@kotrasv.org
Detroit, USA
Tel (248) 619-1601
E-mail detroit@kotradtt.org
Vancouver, Canada
Tel (604) 683-1820
E-mail ktc@kotrayvr.com
Toronto, Canada
Tel (416) 368-3399
E-mail info@kotra.ca
EUROPE
Frankfurt, Germany
Tel (49-69) 2429-920/9
E-mail frankfurt@kotra.or.kr
Hamburg, Germany
Tel (49-40) 3405-740
E-mail info@kotra.de
Munich, Germany
Tel (49-89) 2424-2630
E-mail munich@kotra.or.kr
Paris, France
Tel (33-1) 5535-8888
E-mail paris@kotra.or.kr
Moscow, Russia
Tel (7-495) 258-1627-8
E-mail info@kotra.ru
London, U.K.
Tel (44-20) 7520-5300
E-mail kotra@kotra.co.uk
Brussels, Belgium
Tel (32-2) 205-0088
E-mail kotrabru@kotra.or.kr
Milan, Italy
Tel (39-02) 79-5813
E-mail kotramil@kotra.it
Zurich, Switzerland
Tel (41-44) 202-1232
E-mail ktc@kotra.ch
Stockholm, Sweden
Tel (46-8) 30-8090
E-mail stockholm@kotra.nu
Copenhagen, Denmark
Tel (45) 3347-7221
E-mail info@kotra.dk
Amsterdam, Netherlands
Tel (31-20) 754-6900
E-mail info@koreatradecenter.nl
Vienna, Austria
Tel (43-1) 586-3876
E-mail kotravie@kotra.at
Madrid, Spain
Tel (34-91) 556-6241
E-mail madridktc@kotra.or.kr
ASIA OCEANIA
Singapore
Tel (65) 6426-7200
E-mail kotrasin@singnet.com.sg
Sydney, Australia
Tel (61-2) 9264-5199
E-mail info@kotra.org.au
Melbourne, Australia
Tel (61-3) 9860-0500
E-mail info@kotramelbourne.org.au
Tokyo, Japan
Tel (81-3) 3214-6951
E-mail kotratky@kotra.or.jp
Osaka, Japan
Tel (81-6) 6262-3831
E-mail osaktc@kotra.or.jp
Nagoya, Japan
Tel (81-52) 561-3936
E-mail nagoya@kotra.or.jp
Fukuoka, Japan
Tel (81-92) 473-2005
E-mail fukuoka@kotra.or.jp
Beijing, China
Tel (86-10) 6410-6162
E-mail pekktc@kotra.or.kr
Shanghai, China
Tel (86-21) 5108-8771/2
E-mail shanghai@kotra.or.kr
Guangzhou, China
Tel (86-20) 2208-1600
E-mail canton@kotra.or.kr
Qingdao, China
Tel (86-532) 8388-7931/4
E-mail qdkbc@kotra.or.kr
Hangzhou, China
Tel (86-571) 8110-3099
E-mail ljl88@kotra.or.kr
Nanjing, China
Tel (86-025) 8328-8991
E-mail bonkyung@kotra.or.kr
Hong Kong, China
Tel (852) 2545-9500
E-mail kotra5@kotra.org.hk
Taipei, Taiwan
Tel (886-2) 2725-2324
E-mail kotra.tpe@msa.hinet.net
Kuala Lumpur, Malaysia
Tel (60-3) 2117-7100
E-mail gunwony@kotra.or.kr
Jakarta, Indonesia
Tel (62-21) 574-1522
E-mail jakarta@kotra.or.kr
Mumbai, India
Tel (91-22) 4925-5400
E-mail ktcmumbai@kotra.or.kr
MIDDLE EAST
Dubai, United Arab Emirates
Tel (971-4) 450-4360
E-mail ktcdxb@emirates.net.ae
Invest Korea's
Global Network
You want to do business in Korea but don’t know where to start. Where should you turn? Invest Korea.
As the national investment promotion organization of Korea, Invest Korea helps foreign companies
enter the Korean market. It offers a free one-stop service that includes a wide range of pre-investment,
investment and post-investment support, with offices located around the world.
Contact the Invest Korea office nearest you.
www.Invest Korea.org

KOREA,
Where Success Knows No Limits
www.investkorea.org
13, Heolleung-no, Seocho-gu, Seoul, Republic of Korea (137-749) Tel (82-2)1600-7119 Fax (82-2)3460-7920

Biopharmaceutical march 2015

Recommended

Recommended

More Related Content

What's hot

What's hot (18)

Viewers also liked

Viewers also liked (9)

Similar to Biopharmaceutical march 2015

Similar to Biopharmaceutical march 2015 (20)

Recently uploaded

Recently uploaded (20)

Biopharmaceutical march 2015